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Abstract
Background: Intrinsic and acquired resistance to drug therapies remains a challenge for malignant melanoma
patients. Intratumoral heterogeneities within the tumor microenvironment contribute additional complexity to the
determinants of drug efficacy and acquired resistance.
Methods: We use 3D biomimetic platforms to understand dynamics in extracellular matrix (ECM) biogenesis
following pharmaceutical intervention against mitogen-activated protein kinases (MAPK) signaling. We further
determined temporal evolution of secreted ECM components by isogenic melanoma cell clones.
Results: We found that the cell clones differentially secrete and assemble a myriad of ECM molecules into dense
fibrillar and globular networks. We show that cells can modulate their ECM biosynthesis in response to external
insults. Fibronectin (FN) is one of the key architectural components, modulating the efficacy of a broad spectrum of
drug therapies. Stable cell lines engineered to secrete minimal levels of FN showed a concomitant increase in
secretion of Tenascin-C and became sensitive to BRAFV600E and ERK inhibition as clonally- derived 3D tumor
aggregates. These cells failed to assemble exogenous FN despite maintaining the integrin machinery to facilitate
cell- ECM cross-talk. We determined that only clones that increased FN production via p38 MAPK and β1 integrin
survived drug treatment.
Conclusions: These data suggest that tumor cells engineer drug resistance by altering their ECM biosynthesis.
Therefore, drug treatment may induce ECM biosynthesis, contributing to de novo resistance.
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Background
Molecular studies have determined that aberrant signal-
ing in the mitogen-activated protein kinase (MAPK) sig-
naling cascade (Raf-MEK1/2-ERK1/2) is a crucial step in
melanocytic neoplasia, ultimately deregulating the activ-
ity of key transcription factors that control cell growth,
differentiation, and survival [1]. Specifically, gain of
function mutations in which the 600 valine residue of
the BRAF kinase is substituted with glutamic acid
(BRAFV600E) are present in ~40 % of patients presenting
with malignant melanoma [2]. Survival is enhanced if
detection, treatment and surgical excision occur when
the tumor burden is restricted to a primary site; how-
ever, once the disease has metastasized to distant organs
such as the lung, brain, bone, and liver, prognosis is
poor, with a median survival of ~ 9 months [3]. These
dismal statistics are in part due to the intrinsic resistance
of melanoma to platinum-based chemotherapeutics and
its rapid acquisition of resistance to initial therapeutic
interventions [4, 5]. Present treatment strategies involve
small molecule inhibitors of this mutant BRAF kinase,
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such as vemurafenib and dabrafenib [6, 7]. However,
these therapies are only effective in a subset of patients:
those that harbor the more prevalent BRAFV600E and the
less common BRAFV600K mutations [8]. While drugs tar-
geting this specific isoform are among the most promis-
ing melanoma treatments, patients eventually relapse
due to reactivation of the MAPK signaling cascade, spe-
cifically ERK activity [5, 9]. To overcome de novo resist-
ance, a combinatorial treatment of vemurafenib with a
MEK inhibitor is administered in an effort to combat re-
activation of the MAPK pathway [10–12]. However,
mechanisms that underlie acquired resistance after treat-
ment with multiple inhibitors of this pathway remain
elusive.
Drug resistance has been shown to be mediated by tis-
sue architecture and cell-adhesion [13, 14]. In particular,
cell adhesion-mediated drug resistance (CAM-DR) is an
emergent phenotype associated with cell-cell adhesion
or 2D adhesion to extracellular matrices. Myeloma cells
cultured as monolayers that had adhered to fibronectin
were resistant via upregulation of α4 β1 integrin com-
pared to cells treated in suspension [15]. Similarly,
tumor cells grown as spheroids show increased resist-
ance to therapy compared to the same cells that are dis-
sociated and grown as monolayers [16]. However, the
observed acquired drug resistance following multiple
targeting of the MAPK pathway is not readily explained
by CAM-DR [12]. Because this reactivation attenuates
drug response, it may also contribute to the develop-
ment of acquired resistance [12].
The tumor microenvironment is emerging as a crit-
ical factor in malignant progression, metastasis and
tumor etiology [17, 18]. To explore mechanisms that
drive tumors to overcome and survive under unfavor-
able conditions, we aimed to delineate tumor-induced
microenvironmental responses to the stress induced
by drug therapeutics. Tumor cells actively modulate
the host environment by secreting cytokines that re-
program stromal cells to change the extracellular
matrix (ECM) milieu, thus creating a de novo micro-
environment [17, 18]. While immunotherapy and
monoclonal antibodies targeting tumor angiogenesis
have shown promising results, many microenviron-
mental targets remain underexplored [18]. For ex-
ample, overexpression of secreted ECM proteins such
as fibronectin (FN) has been found in several solid
carcinomas, and postulated to be beneficial for tumor
growth and instrumental in the establishment of an
ideal microenvironment [19]. Furthermore, heteroge-
neous expression of ECM components within tumors
has been observed [20]. Pathologists have long associ-
ated the presence of abundant ECM proteins in tu-
mors with poor prognosis and an expected dismal
response to therapeutic intervention [21].
Recently, a study showed that non-small cell lung can-
cer cells induced FN biogenesis via p38 MAPK in re-
sponse to treatment with cetuximab (targeting the EGF
receptor upstream of the MAPK signaling pathway) [22].
This response was found to blunt the cytotoxic effects of
cetuximab and reduced sensitivity to radiotherapy in in
vitro and in vivo murine models. FN biogenesis may also
reduce the efficacy of drugs targeting the BRAF kinase.
Earlier observations found that a cocoon of ECM pro-
teins, including FN, laminin, collagen IV and Tenascin
C, protect small lung cancer cells from chemotherapy-
induced apoptosis [23]. We hypothesized that melanoma
cells modulate secretion of not only FN, but also other
ECM molecules to survive drug treatment. An important
question is whether baseline ECM expression per se can
predict cell survival and drug resistance. Furthermore, is
upregulation of ECM proteins a reaction to evolutionary
pressure following drug treatment, the result of selection
for pre-existing resistant subpopulations, or a combin-
ation of both? Seeking to identify and determine the
temporal regulation of the secreted ECM proteins, we
focused on two isogenic cell lines to mimic intratumoral
heterogeneity. Our results indicate that tumor cells ad-
just their 3D microenvironment by modulating secretion
of FN and Tenascin-C (TNC), thereby blunting the ef-
fects of MAPK pathway inhibition. We show that only
clones that can modulate their ECM secretion in re-
sponse to pharmaceutical stress survive. Mechanistically,
FN biogenesis via p38 MAP kinase via β1 integrin is in-
duced following pharmaceutical treatment of the MAPK
signaling pathway. Also, our data suggests that biogen-
esis of TNC is an possible alternative to impaired FN
production. This study indicates a critical role for de
novo ECM biogenesis as a mechanism driving acquired
resistance to drugs targeting MAPK signaling in cutane-
ous melanoma.
Methods
Human melanoma cell lines, A375 (cat. No. CRL-1619)
and A375.S2 (cat. No. CRL-1872) cells were obtained from
American Type Culture Collection (ATCC, Manassas, VA)
and cultured on tissue culture flasks as described by the
ATCC. A375 and A375.S2 cells were grown as monolayers
in DMEM high glucose media (Life Technologies, Carlsbad,
CA) supplemented with final volume of 10 % Fetal Bovine
Serum (FBS), 1 % MEM non-essential amino acids, L-
Glutamine, Penicillin and Streptomycin. Cells cultured with
the media was refreshed every 2-3 days.
Animal studies
Animal studies were conducted under protocols ap-
proved by the National Cancer Institute, and the Na-
tional Institutes of Health Animal Care and Use
Committee. Briefly, 5 × 105 A375 cells were injected via
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tail vein into 8–10-week old female nu/nu mice. Three
weeks after injection mice were euthanized and lungs
were extracted and inflated and fixed in 4 % paraformal-
dehyde solution for 12 h and then prepared for histo-
logical staining. Lungs were then embedded in paraffin
prior to sectioning on a microtome. Following antigen
retrieval using xylene, samples were rehydrated and ser-
ial sections; 8 μm thick were labeled for specific stains of
human fibronectin and DAPI.
Human tissue arrays and RNAseq
Human tissue arrays (cat # T386) were purchased from US
Biomax (US Biomax, Rockville, MD) where tissue biopsies of
human normal skin, melanoma with and without metastasis
were examined by immunofluorescence. Briefly, antigen re-
trieval using xylene as described for mouse tissue was con-
ducted and following re-hydration. Samples were stained for
human Fibronectin and DAPI. Public RNAseq datasets were
submitted to National Center for Biotechnology Information
(NCBI) and examined for expression of extracellular matrix
proteins [24] and a search was done for public studies that
involved ECM in melanoma (http://www.ncbi.nlm.nih.gov/
pubmed/?term=tenascin%20C%20AND%20melanoma).
Briefly, normal melanocyte cell lines were compared to mel-
anoma cell lines. In addition, data before and after treatment
in human patients were also mined from publicly available
databases.
3D cell culture
Cells were seeded at a concentration of 2 × 105 cells per
ml of Matrigel (BD Biosciences, San Jose, CA), which
polymerized to form a hydrogel at 37 °C. Media was
added to the hydrogels after 30 min to ensure complete
gelation. Cells were harvested after growth in 2D and
embedded in laminin-rich extra cellular matrix (lrECM)
(BD Biosciences) at 37 °C, in 5 % CO2 as previously de-
scribed [25]. Clonally derived multicellular aggregates
were examined 10 days later for morphology and protein
analysis.
Conditioned media collection and protein preparation
For 2D culture, cells were seeded at 5 × 105 cells per
well in a six well plate with regular media. After 24 h
the regular media was removed and cells were washed
twice with PBS, and serum-free media was added. Con-
ditioned (serum-free) media and cell lysate were col-
lected after 24 h. For 3D culture, cell washing and
refresh with conditioned medium was conducted re-
peated at day 8, following sample collection at day 9. For
3D cultures, cells were also harvested from lrECM for
immunoprecipitation as previously described [25]. Mel-
anoma cells and normal human melanocytes were lysed
in Mammalian Protein Extraction Reagent (Thermo Sci-
entific, Waltham, MA), 1× protease inhibitor cocktail
(Calbiochem, Billerica, MA) and 1× phosphatase inhibi-
tor cocktail 2 & 3 (Sigma-Aldrich, St. Louis, MO)
followed by centrifugation (13,200 rpm, 4 °C, 5 min),
after which the supernatants were stored at -80 °C until
use. Protein concentrations were determined with the
Pierce® BCA Protein Assay kit (Thermo Scientific), using
BSA as the concentration standard. Extracted proteins
were then resolved using 4–12 % Bis-Tris Gels (Life
Technologies) and subsequently transferred to PVDF
membranes (Life Technologies) for immunoblotting.
Western blot analysis
PVDF membranes were washed and blocked with 1 %
BSA in TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4)
containing 0.1 % Tween-20 (TBS-T) and incubated with
the primary antibodies. Next, the membranes were incu-
bated with horseradish peroxidase-conjugated donkey
anti-rabbit IgG (GE Healthcare, Buckinghamshire, UK)
or sheep anti-mouse IgG (GE Healthcare). Finally, the
immunoblot was incubated with an enhanced chemilu-
minescence (ECL) reaction system (Invitrogen) and the
ECL signals were visualized by film. The antibodies were
used at the following dilutions: anti-FN (1:1,000), anti-αv
integrin (1:1,000), anti-β1 integrin (1:1,000), anti-
phospho-p44/42MAPK (1:1,000), anti-p44/42MAPK
(1:1,000), and anti-GAPDH (1:2,000). Except anti-FN
(Origene, Rockville, MD), antibodies are purchased from
Cell Signaling Technology (Danvers, MA).
RNA extraction, reverse transcription, and RT-PCR
Total RNA was extracted using an RNeasy mini Kit (Qiagen,
Valencia, CA) and first-strand complementary DNAs
(cDNAs) were synthesized from 500 ng of each total RNA
preparation with the Quantitect Reverse Transcription kit
(Qiagen) according to the manufacturers’ instructions. The
PCR products were detected by SYBR Safe DNA gel stain
(Invitrogen) after separation in 1 % agarose gel. β-actin was
used as a housekeeping gene to evaluate and compare the
quality of different cDNA samples. The primer sequences
and the expected sizes of PCR products were as follows: Hu-
man FN 1, forward, 5’-ACAGGAAAGAGATGCGCCAA-3’,
reverse, 5’-GGAAGAGTTTAGCGGGGTCC-3’ (403 bp);
Human β-actin, forward, 5’-AGCCTCGCCTTTGCCGA-3’,
reverse, 5’-CTGGTGCCTGGGGCG-3’ (174 bp). AmpliTaq
Gold with GeneAmp and dNTP Mix (Applied Biosystems,
Branchburg, NJ) were used for the RT-PCR analysis. We
used a denaturing step of 94 °C for 5 min, followed by a cyc-
ling program of 94 °C for 10 s, 58 °C (Human FN1) or 60 °C
(Human β-actin) for 60 s, and 72 °C for 60 s for 40 cycles,
and a final holding stage at 4 °C.
Materials for mass spectroscopy
Dithiothreitol (DTT), acetonitrile (ACN), ammonium bi-
carbonate, trifluoretic acids (TFA), and iodoacetamide
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(IAA) were from Thermo Fisher Scientific. Trypsin Gold,
mass spectrometry grade, was from Promega (Madison,
WI). Nanopure water was prepared with use of Milli-Q
water purification system (Millipore, Billerica, MA).
Preparation for in-gel protein digestion
For MS analysis, cells were grown in 1 % dialyzed FBS in
10 cm dishes and conditioned media (CM) collected
every 2 days; protease and proteinase inhibitors were
added immediately. CM was centrifuged at 3,500 rpm
for 30 min to remove cell debris and the supernatant
was concentrated using Amicon Ultra-15, Ultracel-3 K
(ThermoFisher, Cat No: UFC900324) following the man-
ufacturer’s instructions until the volume was reduced to
~300ul. Protein concentration was determined using
BCA assay. 30 μg of proteins were separated using pre-
cast 4–20 % Tris-Glycine SDS-PAGE gels (Life Tech-
nologies). Total protein resolved in the polyacrylamide
gel was stained with Coomassie blue (Sigma). The gel
was destained, reduced, alkylated, and dried for in-gel di-
gestion. Biological replicates at each time point (n = 3)
were run on the same gel and processed simultaneously.
In-gel protein digestion
The dried gel pieces were rehydrated and digested in
80 μL of 12.5 ng/μL Trypsin Gold/50 mM ammonium
bicarbonate at 37 °C overnight. After the digestion was
complete, condensed evaporated water was collected
from tube walls by 5 s centrifugation using a benchtop
microcentrifuge (Eppendorf, Hauppauge, NY). The gel
pieces and digestion reaction were mixed with 50 μL
2.5 % TFA and rigorously mixed for 15 min. The solu-
tion with extracted peptides was transferred into a fresh
tube. The remaining peptides were extracted with 80 μL
70 % ACN/5 % TFA mixture using rigorous mixing for
15 min. The extracts were pooled and dried to comple-
tion (1.5–2 h) in SpeedVac. The dried peptides were
reconstituted in 30 μL 0.1 % TFA by mixing for 5 min
and stored in ice or at −20 °C prior analysis.
LC-MS/MS analysis
Samples were centrifuged at 14,000–16,000 × g for 10 min
to remove particulate material. Five microliters of each
sample were injected into a self-packed fused silica nano
column, which had been pulled to a 5 μm i.d. tip using a
P-2000 CO2 laser puller (Sutter Instruments, Novato,
CA), then packed with 13 cm of 3 μm C18 reverse phase
(RP) particles (Magic C18 AQ 3 μm (Michrom. Biore-
sources, Auburn, CA)) and equilibrated in 5 % aceto-
nitrile, 0.1 % formic acid. Full MS spectra were recorded
on the peptides over a 400 to 2000 m/z range by the Orbi-
trap, followed by five tandem mass (MS/MS) events se-
quentially generated by LTQ in a data-dependent manner
on the first, second, third, and fourth most intense ions
selected from the full MS spectrum (at 35 % collision
energy). Mass spectrometer scan functions and HPLC
solvent gradients were controlled by the Xcalibur data
system (Thermo Finnigan, San Jose, CA).
Database search and interpretation of MS/MS datasets
Tandem mass spectra were searched against a
concatenated target-decoy database containing the for-
ward and reverse sequences of the target database using
the Proteome Discoverer 1.4 and SEQUEST search en-
gine (Thermo Finnigan). The target sequence was down-
loaded from a human Uniprot database (database
released on November 13, 2013) and 124 common con-
taminant proteins. The search algorithm was configured
to specify the following parameters: precursor tolerance,
10 ppm; fragment tolerance, 0.5 Da; static modification,
cysteine carbamidomethylation; and fully tryptic status.
SEQUEST search results from Proteome Discoverer
were further analyzed by Scaffold (Proteome Software
Inc., Portland, OR). The discriminant score was set such
that a false positive rate of 1 % was determined based on
the number of accepted decoy database peptides. Scaf-
fold outputs label-free quantification based on precursor
ion intensity for data from Proteome Discoverer. Precur-
sor intensity refers to the area under an MS1 spectrum
peak corresponding to a specific peptide. We used nor-
malized total precursor intensity to derive quantitative
values in this paper. Statistical analysis was performed by
Qlucore Omics Explorer (Qlucore AB, Lund, Sweden).
Two group comparisons (a paired t-test) was used to com-
pare the mean value of relative abundance based on nor-
malized total precursor intensity from three biological
replicates for each protein identified in conditioned media
collected in day 2 and day 10. The heatmap was generated
based on hierarchical clustering of global protein expres-
sion filtered by the p-value (p < 0.05).
Cell growth inhibition assay by MTT method
Cellular toxicity to drugs was measured by the MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium)
method or CCK-8 (Dojindo Molecular Technologies,
Inc., Rockville, MD) method following manufacturer’s
instructions.
Generation of shFN1 and shFN2 stable cell lines
Plasmids encoding FN knockdown shRNAs were iso-
lated from Mission shRNA Bacteria Glycerol Stocks
NM_002026/TRCN0000293839 and NM_002026/
TRCN0000293840 (designated shFN1 and shFN2, re-
spectively). MISSION® pLKO.1-puro Non-Mammalian
shRNA control plasmid (SCH002, Sigma) was amplified
in MAX Efficiency® DH5α™ Competent Cells (Invitrogen)
for 16 h at 30 oC. Plasmids were extracted from
ampicillin-supplemented LB liquid cultures amplified
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from single colonies over 16 h at 30 oC using Qiagen
Plasmid Midi Kit. Individual plasmids were co-
transfected with lentiviral packaging plasmids (Invitro-
gen) into 293FT cells by Fugene6 Transfection Reagent
(Roche, Basel, Switzerland). Viral supernatant was har-
vested after 48 and 72 h and concentrated by ultracentri-
fugation at 26,000 rpm through a 20 % sucrose gradient.
Lentiviral transduction
Melanoma cells were transduced with virus using
ExpressMag Transduction System (Sigma). Briefly, viral
supernatant was incubated with magnetic beads at room
temperature for 15 min, added to the adherent cells and
placed on a strong magnetic plate at 37 oC for 12 min.
Media was replenished 16 h later and the viral mixture
disposed in compliance with NIH policy. Transduced
cells were selected with 2 μg/ml puromyocin (InvivoGen,
San Diego, CA).
Immunofluorescence
For examination of 2D culture, cells were seeded directly
onto glass chambers with a coverslip-bottomed no. 1.0,
(Nalge, Nunc) according to previously described
methods [25]. For 3D interrogation, samples were pre-
pared as previously described [25]. Samples were rinsed
twice with PBS, fixed with 4 % paraformaldehyde solu-
tion for 20 min, permeabilized with 0.5 % Triton X-100
for 20 min and rinsed and blocked in 5 % horse serum
for 1 h at room temperature. Cells were then incubated
with anti-FN1 antibody (1:100) and anti-actin antibody
(1:100) for 12 h at 4 °C in 5 % horse serum. After incu-
bation with primary antibody, cells were rinsed three
times with PBS and then incubated with secondary anti-
bodies (1:200) for 2 h at 4 °C. Cell nuclei were stained
with DAPI (Sigma). Images were acquired with an up-
right Zeiss LSM 780 Meta confocal microscope (Zeiss,
Jena, Germany).
Imaging specifications
One-photon, confocal, 2-dimensional images of 512 ×
512 pixels (lateral dimensions) were acquired with a 1.4
NA 40 × oil-immersion objective. We sequentially ex-
cited our sample with the 405 nm, 488 nm lines from an
argon ion laser with a power of < 3 % (total power
30 mW) and 546 nm from a solid-state laser (power of
< 10 %). A secondary dichroic mirror, SDM 560, was
employed in the emission pathway to delineate the red
(band-pass filters 560–575 nm) and green (band-pass fil-
ters 505–525 nm) and blue channels (480-495 nm) at a
gain of 400 on the amplifier. The laser power for the
543 nm setting was set at < 3 % of the maximum power
and the gain on the detectors was set to 450.
3D soft agar assay
Anchorage-independent proliferation was quantified by
soft agar assay. Cells were suspended in 1 mL of 0.36 %
(w/v) bacto-agar (BD Biosciences) overlaid by a 0.6 %
(w/v) bacto-agar support in 6-well plates in triplicates at
densities of 5 × 103 cells per well for A375, A375.S2,
A375Scr, A375 shFN2, A375.S2 Scr, A375.S2 shFN2
lines, respectively. Plates were incubated at 37 °C in nor-
moxic conditions. Pathway inhibitors were used at the
following concentrations: 3.0 μM cisplatin (DNA-cross-
linking agent), 3.0 μM VX-11e (ERK inhibitor), 3.0 μM
vemurafenib (BRAFV600E inhibitor) (Chemietek, Indian-
apolis, IN), and 50 nM paclitaxel (microtubule stabiliz-
ing agent) (Life Technologies). Pathway inhibitors were
administered at the beginning of the experiment or initi-
ated 14 days later. At the end of the experiment, wells
were stained with 0.5 μg/mL of nitrotetrazolium blue
chloride (Sigma-Aldrich). Colonies with > 20 μm in
diameter were counted using the Bioreader Software and
a BioSys BioCount 4000 Pro machine. Clonogenic sur-
vival for each line and condition was plotted as fre-
quency of colony size normalized to a gaussian
distribution. Experiments were performed in triplicate.
Results
Distinct temporal regulation of extracellular matrix
protein production in response to drug treatment is
dynamic
Public RNAseq datasets submitted to National Center
for Biotechnology Information (NCBI) were examined
for expression of extracellular matrix proteins. Six
melanoma cell lines consistently showed higher ex-
pression of FN1 (fibronectin) than pooled human
melanocyte controls (Fig. 1a) [24]. The only other
known ECM-related transcript consistently upregu-
lated at the RNA level was TNC (Tenascin-C), which
has been shown to be involved in melanoma progres-
sion [26]. Moreover, when a separate dataset was ex-
amined for RNAseq-based expression levels in human
patients, pre- and post-vemurafenib (first column),
dabrafenib (second column) and trametinib (third col-
umn) treatment, the same pattern of expression (pre-
sented as log2 (control)) was observed, with FN1 and
TNC, but not other ECM-related transcripts, consist-
ently upregulated at the RNA level [27] (Fig. 1b). This
may occur in response to treatment, or due to select-
ive survival of tumor cells that originally expressed
higher levels of the ECM.
To determine the dynamic contributions made by
tumor cells to the establishment of a de novo tumor
microenvironment, we selected A375 and its derivative
clone A375.S2, which are isogenic human melanoma cell
lines that reflect established intratumoral heterogeneity.
These cell lines harbor a BRAFV600E mutation and are
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tumorigenic when injected into immune-compromised
mice. Using a tandem mass spectrometry-based tech-
nique (LC-MS/MS), we analyzed the culture media
conditioned by the parent and its derivative cell lines
over the course of 10 days in 2D culture (Fig. 1c).
We identified many ECM-related proteins were com-
monly or differentially secreted. The amount of these
secreted ECM components was modulated as a func-
tion of time, thus illustrating the dynamics of tumor
biofilm formation, and baseline secretion was also
consistently distinct between the clones (Fig. 1d). Se-
cretion of fibronectin (FN), in particular, varied sig-
nificantly in amount and timing in A375 and A375.S2
cell lines. We thus reasoned that using the 3D biomim-
etic platforms, we could further address the heterogeneity
of ECM secretion and dynamics, particularly as it relates
to acquired resistance.
FN deposition is increased in metastatic melanoma cells
Immunoblots of proteins extracted from cell lysates (CL)
and conditioned media (CM) show that the A375 cells
secreted less FN than the A375.S2 cells when they were
cultured in 2D environment (Fig. 2a). We confirmed
these cell lines express FN1 via RT-PCR (Additional file
1: Figure S1b). When these cell lines were cultured in
laminin-rich ECM (lrECM), a complex matrix more
closely mimicking in vivo conditions, both cell lines se-
creted more FN than in 2D culture (Fig. 2a). The A375
cells formed large, irregular “grape-like” aggregates,
whereas A375.S2 clone formed smaller compact
“masses” (Fig. 2b). The mean cross-section area and cir-
cularity of the A375.S2 colonies were significantly differ-
ent from the A375 colonies (Additional file 1: Figure
S1C). These differences in morphology and shape were
similar to phenotypes observed for 3D culture of breast
Fig. 1 Distinct temporal regulation of ECM in response to drug treatment and in vitro culture conditions. a RNA sequence data show that FN is
upregulated in melanoma cell lines and patients who have become resistant as a result of multiple drug treatments. Bar charts showing RNA
sequence counts for control melanocytes compared to seven melanoma cell lines treated with BRAF inhibitor, where the red line shows the
basal level of controls. b RNAseq-based expression levels for patients that were biopsied pre- and post-vemurafenib (red), dabrafenib (blue), and
trametinib (green) treatment. c Schematics of experimental protocol using MS to identify secretomes of the isogenic human melanoma clones.
d Dynamics of secreted ECM components show that temporal evolution of tumor biofilm differs as a function of tumor heterogeneity in cell
culture. Quantitative comparison of ECM proteins in conditioned media reveals temporal differences in the amount of secreted proteins,
highlighting the heterogeneity of baseline ECM biogenesis. * indicates a p value < 0.05, ** indicates a p value < 0.01 and *** indicates a
p value < 0.001
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tumor cells [25]. Additionally, confocal immunofluores-
cence revealed that cells secreted FN and assembled FN-
globular networks in 3D lrECM culture, in contrast to
the fibrils observed in 2D culture (Fig. 2b). The im-
munofluorescence of colonies grown in soft agar further
confirms that both clones can assemble FN structures in
a foreign microenvironment, and that this FN is tumor-
derived (Fig. 2c). To establish the relevance to human
disease progression, we determined that FN levels vary
as a function of malignancy in human tissue arrays.
Compared to normal skin and non-metastatic melan-
oma, we observed increased FN deposition at sites of
melanoma metastasis (Fig. 2d). FN deposition was spe-
cifically localized to the metastatic lesions rather than
adjacent normal lung or lymph epithelium.
Difference in tumor architecture affects MAPK inhibitor
sensitivity
Tumor architecture has been shown to be an important
factor for determining drug responses in breast tumors
cultured in 3D lrECM compared to the tissue culture
[28]. To determine whether the efficacy of drugs target-
ing the MAPK pathway may be similarly governed by
tissue architecture, we recreated an established tumor
and drug regimen using a 3D soft agar assay, in which
we administered drug treatment once every three days.
This time frame was designed to establish tumors that
lacked necrotic cores. Then we administered drug treat-
ment that mimics clinical settings (Fig. 3 Top panel).
Colonies derived from A375 cells were largely insensitive
to cisplatin, vemurafenib, vx-11e and vemurafenib + vx-
Fig. 2 Fibronectin is a key architectural component in tumor biofilm in vitro and in vivo. a Top panel- Schematic of 3D sample preparation where cells
were embedded in laminin-rich ECM (lrECM) and cultured for 10 days to recapitulate growth of melanoma with a basement membrane. Bottom panel-
Immunoblots showing an increase in the levels of FN in conditioned media (CM) and cell lysates (CL) when cells are cultured in 2D vs. 3D. The A375 clone
shows a threefold increase in FN production, whereas the A375.S2 clone shows a modest increase. Numbers next to the immunoblots represent fold of
increase in fibronectin expression. b Micrographs showing the differences in assembly of secreted FN (green) between A375 and A375.S2 in both 2D and
3D culture. Green arrows show the locations of FN. Scale bars for 2D represent 5 μm and for 3D, 20 μm, respectively. c Schematic of 3D sample preparation
for anchorage-independent growth where cells were embedded in soft agar and cultured for 28 days. Micrographs show that all FN is tumor-generated in
this assay. Scale bars represent 50 μm. d Top panel- micrographs of human tissue arrays of normal skin as well as malignant and metastatic melanoma
show that there is an increase in FN deposition within the tumor mass as a function of increasing metastatic potential, whereas FN deposition is restricted
to the dermis in normal skin epithelium. Micrographs show increased FN deposition within the metastatic lung lesion compared to normal adjacent lung
epithelium in the mouse following tail vein injection of melanoma cells. Scale bars represent 50 μm and 20 μm for the inset
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11e co-incubation. Contrary to A375 cells, the A375.S2
colonies showed increased sensitivity to drugs targeting
the MAPK signaling pathway as determined by a reduc-
tion of number of colonies concomitant with reduced
colony diameters (Fig. 3 Bottom Panel).
We reasoned that the ability to modulate FN secretion
might mediate survival in the parental clone as com-
pared to the A375.S2 cells. To determine if heterogen-
eity in FN deposition mediated the observed differential
drug sensitivity between the clones, we generated two
stable cell lines, named shFN1 and shFN2, producing re-
duced levels of FN using two shRNAs, respectively. In
addition, a scramble control (Scr) was made. These three
cell lines were cultured in 3D using soft agar for 21 days
before protein extraction. Immunoblots revealed that an
approximately 80 % reduction of FN protein was found
in shFN1 and shFN2 cell lines, compared to the Scr
cells. However, the shFN1 and shFN2 cells did not show
significant difference in ERK activation (Fig. 4a). To de-
termine if cell-ECM crosstalk was impaired with reduced
FN biogenesis, we examined expression of integrins that
facilitate cross talk with FN, and modulate cellular at-
tachment to the ECM in vivo. Comparing the shFN1
and shFN2 cells, αv integrin expression was different but
β1 integrin was not (Additional file 1: Figure S2). Be-
sides, shFN1 and shFN2 cells expressed higher levels of
β1 integrin than the wildtype and Scr counterparts,
while FN knockdown did not affect αv integrin expres-
sion level (Additional file 1: Figure S2). This highlights
that shFN cells maintain the machinery for cell-ECM
communication, and suggests that β1 integrin levels cor-
relate with FN modulation. Similarly, we asked if altered
cell cycle progression may account for differential sensi-
tivity. We determined that the cell cycle was unchanged
in shFN cells compared to Scr cells (Additional file 1:
Figure S3).
FN deficiency increases Tenascin-C
We next examined the secretome profiles of cells cul-
tured in 3D lrECM. Culture medium from A375 and
A375.S2 cells were collected before and after drug treat-
ment (Fig. 4b). In A375 Scr cells, FN was found to in-
crease at the cellular level in response to vx-11e,
vemurafenib and paclitaxel treatments (Fig. 4c- Left
panel). The surviving population tuned FN biogenesis
under stress, particularly noting the dramatic increase
following BRAF and ERK inhibition, but not for cisplatin
and paclitaxel. FN-deficient aggregates, on the other
hand, showed upregulation of Tenascin-C (TNC) in re-
sponse to drug treatment. In contrast, the A375.S2 cells
showed only a modest response despite displaying higher
baseline levels of FN, which correlates with the reduced
vitality of A375.S2 colonies cultured in agar (Fig. 4c-
Right panel).
Fig. 3 A375 and A375.S2 colonies show a differential response to drug treatment. Schematic showing the timing of drug administration for cells
embedded in 3D soft agar with treatment commencing after colony formation. Growth of isogenic colonies in 3D soft-agar assays shows differential
response to drug treatment. A375 colonies (Top panel) are largely insensitive to drug treatment, whereas A375.S2 (Bottom panel) cells form
fewer colonies of smaller size as determined by diameter
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FN reduction sensitizes melanoma colonies to cisplatin,
vemurafenib and Vx-11e
To determine whether FN reduction in melanoma cells
could affect drug sensitivity, we assessed the sensitivity
of the A375, A375.S2, with their Scr and shFN clones,
with vemurafenib, vx-11e and cisplatin cultured in 2D
and 3D environments. The half maximal inhibitory con-
centration (IC50), as determined from the viability curves
constructed post-MTT assay in 2D, remains unchanged
despite the reduced levels of FN (Fig. 5a). By measuring
cellular uptake of nitrotetrazolium blue chloride, we
confirmed that the cells were metabolically active (Add-
itional file 1: Figure S4B). However, we confirmed
changes in intracellular signaling in response to treat-
ment by assessing ERK activity in addition to MAPK ac-
tivation (Additional file 1: Figure S4A), suggesting that
observed sensitivity of FN-deficient colonies correlates
with molecular events tied to 3D architecture establish-
ment. Both Scr and shFN cell lines responded to
treatment when BRAFV600E and ERK inhibitors were ad-
ministered before colony formation (Additional file 1:
Figure S4C). Interestingly, normal resistance to cisplatin
observed in wild type malignant melanoma cells was di-
minished in the shFN cell lines in this assay. When cells
were allowed to form colonies, those colonies derived
from control Scr cells remained largely intact and in-
sensitive to any of the drugs administered (Fig. 5b).
shFN colonies were sensitive, showing a reduced number
of surviving colonies following drug treatment (Fig. 5b).
FN-depleted A375.S2 colonies showed an exaggerated
sensitivity to drugs targeting MAPK signaling (Fig. 5c).
FN expression is part of signaling pathway in drug
response
To understand the role of FN architecture in determin-
ing malignant melanoma tumor sensitivity to treatment,
we sought to determine whether drug uptake was en-
dogenously affected in shFN cells, or if assembly of
Fig. 4 A375 tumor cells that survive pharmacological inhibition of MAPK signaling pathway upregulate FN. a Immunoblots show the reduction of
FN levels using shRNA has a modest effect on ERK activity for two shRNA FN constructs (shFN1 and shFN2). b Schematic of drug treatment
regimen: tumors were grown in 3D from single cells embedded in laminin-rich ECM (lrECM) for 9 days, replenished with serum-free media for
24 h, followed by drug treatment in serum-containing media, and replenished for 24 h with serum-free media for harvesting. c Immunoblots
show differential response of isogenic clones to drug treatment. The A375 clone shows an increase in FN production, whereas the A375.S2 clone
shows little in response to drug treatment. Immunoblots of conditioned media (CM) and cell lysates (CL) pre- and post-drug treatment show an
increase in FN levels in response to vx-11e, vemurafenib and combined treatment with vemurafenib and vx-11e, but not to cisplatin. TNC was
upregulated in the shFN2 aggregates in response to treatment. Equal amounts of protein from conditioned media were analyzed on separate
gels for measuring FN and TNC levels
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bioavailable fibronectin would rescue the observed sensi-
tivity. First, we added exogenous fluorescent-labeled FN
to Scr and shFN cells that were cultured in 3D lrECM.
As a further control, the Scr cell line was incubated with
and without RGD motif-blocking peptides. We observed
assembly of FN into de novo cortical rings formed 48 h
post-addition by control cells (Fig. 6a). Immunoblots re-
vealed that FN levels remained constant despite the
presence of blocking peptides (Fig. 6b). However, fewer
shFN aggregates assembled cortical FN (Fig. 6c). Using
fluorescent conjugated taxol, we found that drug uptake
in 2D culture was unaffected (Additional file 1: Figure
S5), but fluorescence recovery after photobleaching
(FRAP) in shFN 3D aggregates revealed that drug recov-
ery time was modestly slower (Fig. 6d).
These data suggested in addition to providing a phys-
ical barrier, secreted FN might be part of an essential
signaling cascade in responds to extracellular stress. We
observed that p38 signaling was increased after drug
treatment (Fig. 4c). Combined treatment with
BRAFV600E and p38 MAPK inhibitors consequently re-
duced FN secretion in Scr cells, and lowered TNC
expression in shFN cells (Fig. 7a). This suggests that p38
MAPK activity is necessary to fully upregulate FN (or
TNC if FN production is impaired) in response to drug.
Earlier we suggested a role for β1 integrin in similarly
modulating FN biogenesis. Cells grown in the presence
of β1 integrin-blocking antibody, BRAF and p38 inhibi-
tors produce drastically less FN (Fig. 7b). p38 MAPK
and β1 integrin inhibition prevented malignant melan-
oma cells from modulating FN expression, which was
shown to be essential in surviving pharmaceutical stress.
Discussion
Treatment strategies for metastatic malignant melanoma
have significantly improved due to our current under-
standing of the molecular basis of tumor etiology [29].
Targeted therapy based on BRAF V600E status has
yielded dramatic results and disease regression has been
observed. In spite of recent progress, the stark reality is
that current treatments do not yet achieve durable re-
sponses due to melanoma intratumoral heterogeneity.
The remodeling of the ECM results in changes within
the microenvironment adding further complexity to the
Fig. 5 Reduced FN render previously insensitive, 3D tumor aggregates susceptible to a broad range of drugs. a Viability curves of Scr and shFN
cells treated with MTT in 2D show negligible differences for pharmacological inhibitors cisplatin, vemurafenib and vx-11e. b Schematic showing
the timing of drug administration for cells embedded in 3D soft agar with treatment commencing after colony formation. A375-Scr cells are
insensitive to inhibitors of the MAPK pathway, whereas A375 shFN2 cells show increased sensitivity to MAPK inhibition at dosages determined
from the IC50 curves. c Similar comparison of colonies formed from A375. S2-Scr cells show greater sensitivity to inhibitors of the MAPK pathway.
Colonies of A375.S2 shFN2 cells were further reduced in number following treatment by all inhibitors. Significance was determined by student’s
t- test, comparing within conditions to control where * indicates p <0.05, ** indicates p <0.01, *** indicates p <0.001, **** indicates a p <0.0001
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determinants of drug efficacy and the likelihood of
acquired resistance. We present a novel mechanism
by which cells tune their ECM secretion, namely FN
via p38 MAPK –β1 integrin, in response to pharma-
ceutical inhibition of the MAPK signaling pathway in
cutaneous melanoma cell lines, especially in 3D cul-
ture system. Here we show that when FN biogenesis
is impaired, increased TNC expression is observed,
suggesting a compensatory mechanism to attenuate
drug treatment. By using the A375 cell lines that
mimic tumor heterogeneity, we determined that only
clones that can modulate FN biogenesis survive
pharmaceutical intervention. These results, in con-
junction with similar observations in patient data,
suggest a role for ECM biosynthesis in the emergence
of de novo resistance.
Extracellular matrix proteins (ECMs) are often ob-
served to be abundantly expressed by tumor cells in
comparison to their normal counterparts. Analysis of pa-
tient data confirmed that overexpression of ECM pro-
teins such as FN and TNC are likewise observed in
patients that had acquired de novo resistance from initial
drug therapies. Similar outcomes have been noted for
breast, laryngeal, urothelial and non-small-cell lung can-
cers [22, 30–32]. Using proteomics and immunofluores-
cence, we determined a distinct temporal distribution of
secreted ECM components and visualized the assembled
ECM scaffold for two isogenic malignant melanoma
clones. We determined that melanoma cells modulate
the secretion of many ECM proteins that are also impli-
cated as potential biomarkers for patients suffering from
metastatic disease [33]. Recently, ECM signatures were
Fig. 6 FN assembly is impaired in shFN1 cells cultured in 3D lrECM a Representative images of aggregates 2 days after exogenous FN conjugated to
Rhodamine (Rho) is added to 3D lrECM culture (inset shows no FN assembly on day 0). IgG control and integrin-blocking peptides were compared in
shFN and Scr cells. Scale bar represents 20 μm. b Immunoblots show that FN and phospho-p38, but not other proliferation markers in the presence of
blocking peptides. c Graph show a reduction in the number of shFN2 colonies that assemble exogenous FN as a cortical ring compared to Scr colonies
d Drug uptake is only modestly slower as determined from fluorescent recovery after photobleaching. Graph showing that the recovery time for drug
influx is only modestly slower for shFN2 3D aggregates. Conditioned media to probe FN and TNC was run on separate gels where equally
loaded protein
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assigned to breast and ovarian tumors of differing meta-
static potential [34, 35]. These ECM signatures were not
solely derived from the stromal cell secretions, but also
included contributions from the tumor cells themselves
[35]. Here, we go a step further to follow the evolution
of a melanoma-derived ECM signature. In particular, the
secretion patterns of the two clones were significantly
different with respect to relative amounts of FN, perios-
tin, TNC, laminins and vitronectin (Fig. 1c). FN also dif-
fered architecturally; fibrils were predominantly
observed in one clone vs. globular scaffolds for the other
(Fig. 2d). FN fibril assembly is regulated by tensional
reorganization of actin via stress fibers for cells cultured
in 2D [36–38]. Actin structures convey different mech-
anical properties based on spatial organization in 2D,
and regulate specific motilities in 3D [25, 39]. Further-
more, cell motility regulates ECM remodeling and plays
a role in the final architecture of the ECM scaffold [40].
These two cell lines show differential adhesion forces
when placed in a 2D biomimetic platform simulating
cell-ECM interactions [41]. Additionally, differences in
FN conformation dictate the availability of binding sites
that affect signaling cascades associated with growth, mi-
gration and adhesion [42, 43]. In our system, it remains
to be seen if there is a difference in tensional regulation
and whether globular vs. fibril conformations show dif-
ferential drug sensitivity.
In this study, we observed that FN was differentially
secreted and assembled when tumor cells harboring the
BRAFV600E mutation were cultured in 2D vs. in a bio-
mimetic 3D platform [44]. In vivo, tumor cells have ac-
cess to various sources of fibronectin, namely the plasma
and stroma. As a surrogate basement membrane gel, the
laminin-rich ECM contains several ECM proteins and
cytokines, including minute amounts of FN [40], How-
ever, previous studies have shown that FN-null cells
poorly assemble FN fibrils when exogenous FN is added
to them [45]. We confirmed that a reduced number of
shFN cells assembled exogenous FN compared to Scr
cells in in vivo and in vitro 3D culture (Figs. 3 and 7).
Growth inhibition when FN has been compromised has
also been observed for other types of cancer [46]. This
was due in part to reduced expression of β1 integrin and
alterations of the cell cycle; however, in our system the
short hairpin did not alter the cell cycle or reduce β1 in-
tegrin levels. Melanoma-derived conditioned media was
shown to stimulate in vivo FN expression in target or-
gans preceding future metastatic lesions. This
phenomenon was also attributed to resident fibroblasts
that create the “pre-metastatic niche” [47]. Our data sug-
gests that metastatic melanoma also modulates its
“tumor niche” by secreting and assembling its own ECM
scaffold to survive drug treatment. Our results suggest
that modulation of FN secretion serves as a response to
external stress and may be separate from the remodeling
of stromal components observed during initial malignant
transformation.
Melanoma is largely resistant to platinum treatments
since several factors such as drug uptake, increased ef-
flux, extracellular interaction via cell adhesions and slow
cycling cells may contribute to intrinsic resistance [48–
50]. In our system 3D architecture did mitigate drug effi-
cacy, as only a partial killing was achieved for FN-null
tumor aggregates and minimal FN secretion was ob-
served in response to cisplatin.
It has been previously reported that activation of the
ERK/MAP kinase in melanoma cells stimulates FN bio-
genesis via the early growth response-1 transcription fac-
tor (Egr-1) [51]. High FN and Egr-1 levels were found in
BRAFV600E mutant cells and patient tumors. However,
stimulation of the ERK pathway was insufficient to in-
duce FN biogenesis in normal melanocytes [51]. Here,
inhibition of the ERK pathway activates FN biogenesis
via p38MAPK and β1 integrin signaling in melanoma
Fig. 7 FN assembly and Tenascin-C are mediated by p38 MAPK and
β1 integrin. a Immunoblots reveal no change in FN levels (cell lysate
and conditioned media) when p38 MAPK is inhibited. b Immunoblots
reveal that β1 integrin modestly affects FN secretion, but significantly
increases TNC in both cell lines (Scr and shFN2)
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cells but not in melanocytes. In a previous study, β1 integ-
rin inhibition targeting FN has increased radio sensitization
of breast tumor cells in 3D culture [52]. However, non-
malignant breast cells undergo apoptosis following treat-
ment with a β1-integrin function-blocking antibody,
whereas the malignant counterpart cells appear resistant to
this treatment [53, 54]. Integrin blocking treatment is suc-
cessful only if there is a differential response between nor-
mal tissue and its malignant counterpart. Thus, in addition
to multiple targets of MAPK signaling, concomitant treat-
ment with a p38 inhibitor may be a better strategy to pre-
vent acquire drug resistance due to FN biosynthesis.
However, in the case of metastatic disease, acute treatment
with integrin-blocking antibodies may be useful to over-
come de novo resistance. Nevertheless, alternative strategies
to overcome FN mediated cell adhesion mediated drug re-
sistance have been reported that could reverse drug resist-
ance in leukemia and solid tumors [55, 56].
In normal cells during early embryogenesis, FN pro-
vides a scaffold for the assembly of other ECM proteins
to direct organ specificity and fate, so we reasoned that
other ECM proteins would be altered when FN biogen-
esis is affected [57]. In fact, we observed an increase in
Tenascin-C biogenesis by shFN melanoma cells. Here,
we show that drug treatment may induce ECM biosyn-
thesis, contributing to de novo resistance. This must be
considered when designing therapeutic interventions.
Our findings suggest that modulation of tumor ECM
biogenesis mimics the behavior of bacteria that assemble
a biofilm in response to nutrient deficiencies, antibiotics
and oxidative stress [58]. This biofilm acts as a physical
barrier and signaling reservoir to communicate sensing
of deleterious conditions. Tumor cells may use this se-
creted “biofilm” to communicate and communally enter
a state of dormancy until environmental conditions are
more favorable. If we can understand the mechanisms
underlying tumor biofilm assembly, we may be able to
seize a novel opportunity for therapeutic intervention.
Conclusions
In this study, we observed an increase in Tenascin-C bio-
genesis in melanoma cells expressing reduced level of fi-
bronectin, suggesting a compensatory mechanism in
response to drug treatment. We also showed that drug
treatment could induce ECM biosynthesis, contributing to
de novo resistance. Our findings suggest that modulation
of tumor ECM biogenesis mimics the behavior of bacteria
that assemble a biofilm in response to nutrient deficien-
cies, antibiotics and oxidative stress.
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